Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Benzinga · 1d ago
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.